Processing

Please wait...

Settings

Settings

Goto Application

1. WO2013049722 - COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE

Publication Number WO/2013/049722
Publication Date 04.04.2013
International Application No. PCT/US2012/058121
International Filing Date 28.09.2012
IPC
C07D 413/14 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
413Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
14containing three or more hetero rings
A61K 31/497 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
4965Non-condensed pyrazines
497containing further heterocyclic rings
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 31/4745
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
4738ortho- or peri-condensed with heterocyclic ring systems
4745condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
A61K 31/497
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
4965Non-condensed pyrazines
497containing further heterocyclic rings
A61K 31/7068
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7068having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 33/243
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
24Heavy metals; Compounds thereof
243Platinum; Compounds thereof
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61N 5/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
5Radiation therapy
10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
Applicants
  • VERTEX PHARMACEUTICALS INCORPORATED [US]/[US] (AllExceptUS)
  • CHARRIER, Jean-Damien [FR]/[GB] (US)
  • STORCK, Pierre-Henri [FR]/[GB] (US)
  • STUDLEY, John [GB]/[GB] (US)
  • PIERARD, Francoise Yvonne, Theodora Marie [BE]/[GB] (US)
  • DURRANT, Steven, John [GB]/[GB] (US)
  • LITTLER, Benjamin, Joseph [GB]/[US] (US)
  • ANGELL, Paul (US)
  • HUGHES, Robert, Michael [GB]/[US] (US)
  • SIESEL, David, Andrew [US]/[US] (US)
  • URBINA, Armando [US]/[US] (US)
  • ZWICKER, Carl [US]/[US] (US)
  • LOCONTE, Nicholas (US)
  • BARDER, Timothy (US)
Inventors
  • CHARRIER, Jean-Damien
  • STORCK, Pierre-Henri
  • STUDLEY, John
  • PIERARD, Francoise Yvonne, Theodora Marie
  • DURRANT, Steven, John
  • LITTLER, Benjamin, Joseph
  • ANGELL, Paul
  • HUGHES, Robert, Michael
  • SIESEL, David, Andrew
  • URBINA, Armando
  • ZWICKER, Carl
  • LOCONTE, Nicholas
  • BARDER, Timothy
Agents
  • CHE, Jennifer, G.
Priority Data
61/541,86130.09.2011US
61/554,17401.11.2011US
61/620,69805.04.2012US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE
(FR) COMPOSÉS UTILES COMME INHIBITEURS DE KINASE ATR
Abstract
(EN) The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; solid forms of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I-l : wherein the variables are as defined herein. Additionally, the compounds of this invention have formula II: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein.
(FR) La présente invention concerne des composés utiles comme inhibiteurs de protéine kinase ATR. L'invention concerne également des compositions pharmaceutiquement acceptables comprenant les composés de cette invention, des procédés de traitement de divers maladies, troubles et affections au moyen des composés de cette invention, des procédés de préparation des composés de cette invention, des intermédiaires pour la préparation des composés de cette invention, des formes solides des composés de cette invention, et des procédés d'utilisation des composés dans des applications in vitro, comme l'étude des kinases dans des phénomènes biologiques et pathologiques, l'étude des voies de transduction de signaux intracellulaires médiées par ces kinases, et l'évaluation comparative de nouveaux inhibiteurs de kinase. Les composés de cette invention ont la formule I-1, dans laquelle les variables sont définies ici. En outre, les composés de cette invention ont la formule II, ou un sel pharmaceutiquement acceptable de celle-ci, dans laquelle les variables sont définies ici.
Latest bibliographic data on file with the International Bureau